IL17A and viral infectious disease: Further, levels of IL-17A in patients hospitalized with viral infections, including SARS-CoV2 or MERS, increase 3-–20-fold over baseline levels [54–57] and can exceed the EC50 for the erythroid stimulatory effect of IL-17A in vitro (2 ng/mL) (S8 Table).